Abstract:Chun Zeng, 1, 2 Jing Wang, 3 Mingwei Li, 4 Huina Wang, 4 Feng Lou, 4 Shanbo Cao, 4 Changyu Lu 3 1 Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, Beijing, People's Republic of China; 2 China National Clinical Research Center for Neurological Diseases, Beijing, People's Republic of China; 3 Department of Neurosurgery, Peking University International Hospital, Beijing, People's Republic of China; 4 Acornmed Biotechnology Co., Ltd, Beijing, People's Republic of China Correspondence: Changyu Lu Department of Neurosurgery, Peking University International Hospital, Beijing, People's Republic of China Tel +8669006144 Email Shanbo Cao Acornmed Biotechnology Co., Ltd, Floor 18, Block 5, Yard 18, Kechuang 13 Road, Beijing, 100176, People's Republic of China Tel +8653606156 Email Background: Tremendous efforts have been made to explore biomarkers for classifying and grading glioma. However, the majority of the current understanding is based on public databases that might not accurately reflect the Asian population. Here, we investigated the genetic landscape of Chinese glioma patients using a validated multigene next-generation sequencing (NGS) panel to provide a strong rationale for the future classification and prognosis of glioma in this population. Methods: We analyzed 83 samples, consisting of 71 initial treatments and 12 recurrent surgical tumors, from 81 Chinese patients with gliomas by performing multigene NGS with an Acornmed panel targeting 808 cancer-related hotspot genes, including genes related to glioma (hotspots, selected exons or complete coding sequences) and full-length SNPs located on chromosomes 1 and 19. Results: A total of 76 (91.57%) glioma samples had at least one somatic mutation. The most commonly mutated genes were TP53, TERT, IDH1, PTEN, ATRX , and EGFR . Approximately one-third of cases exhibited more than one copy number variation. Of note, this study identified the amplification of genes, such as EGFR and PDGFRA , which were significantly associated with glioblastoma but had not been previously used for clinical classification (P< 0.05). Significant differences in genomic profiles between different pathological subtypes and WHO grade were observed. Compared to the MSKCC database primarily comprised of Caucasians, H3F3A mutations and MET amplifications exhibited higher mutation rates, whereas TERT mutations and EGFR and CDKN2A/B copy number variations presented a lower mutation rate in Chinese patients with glioma (P< 0.05). Conclusion: Our multigene NGS in the simultaneous evaluation of multiple relevant markers revealed several novel genetic alterations in Chinese patients with glioma. NGS-based molecular analysis is a reliable and effective method for diagnosing brain tumors, assisting clinicians in evaluating additional potential therapeutic options, such as targeted therapy, for glioma patients in different racial/ethnic groups. Keywords: glioma, molecular pathology, molecular biomarker, copy number variations, multigene NGS panel Gliomas are the most common tumors in the brain and central nervous system (CNS). 1 However, gliomas comprise a diverse collection of entities, each with its own unique clinical and biological characteristics. 2 According to the 2016 World Health Organization (WHO) standards, gliomas include grade II–III astrocytoma (A) and oligodendroglioma (O), as well as grade IV glioblastoma (GBM) and diffuse midline glioma (DMG). 3 Previous brain tumor classification was primarily based on histopathological characteristics confirmed by hematoxylin and eosin staining (H&E) and immunohistochemistry (IHC). Detection of IDH mutations, 1p/19q codeletion, and H3F3A mutations (midline position) are now recommended according to their histologic diagnosis. 4–6 Emerging evidence has shown that inclusion of molecular characterization could improve the prognostic and predictive stratification of CNS tumors. 7–9 In fact, many key mutations in the TERT, ATRX, TP53 , and EGFR genes found in gliomas 10 , 11 could be used as diagnostic, prognostic, and therapeutic biomarkers. However, these mutation markers have not been included in the latest WHO CNS tumor classification criteria; 3 therefore, they are not used in ro -Abstract Truncated-

Chinese Glioma Genome Atlas (CGGA): A Comprehensive Resource with Functional Genomic Data for Chinese Glioma Patients

Chinese Glioma Genome Atlas (CGGA): A Comprehensive Resource with Functional Genomic Data from Chinese Glioma Patients.

Genomic profiling identified novel prognostic biomarker in Chinsese glioma patients.

Comprehensive Molecular Characterization of Chinese Patients with Glioma by Extensive Next-Generation Sequencing Panel Analysis

Comprehensive genomic characterization defines human glioblastoma genes and core pathways

The Comparison Genomics Analysis with Glioblastoma Multiforme (GBM) Cells under 3D and 2D Cell Culture Conditions

Mining TCGA database for genes of prognostic value in glioblastoma microenvironment

An automated archival single-nucleus total RNA sequencing platform mapping integrative and retrospective cell atlas of gliomas

Integrative Genomic and Transcriptomic Analysis of Primary Malignant Gliomas Revealed Different Patterns Between Grades and Somatic Mutations Related to Glioblastoma Prognosis

Identification of Novel Human Glioblastoma-Specific Transcripts by Serial Analysis of Gene Expression Data Mining

Comparative genomic landscape of lower-grade glioma and glioblastoma

Identification of Key Immune and Cell Cycle Modules and Prognostic Genes for Glioma Patients through Transcriptome Analysis

CGPA: multi-context insights from the cancer gene prognosis atlas

Identification of robust diagnostic and prognostic gene signatures in different grades of gliomas: a retrospective study

Analysis of Differentially Expressed Genes Based on Microarray Data of Glioma.

Genomic Landscapes by Multiregion Sequencing Combined with Circulation Tumor DNA Detection Contribute to Molecular Diagnosis in Glioblastomas

Integrating Genomic Data with Transcriptomic Data for Improved Survival Prediction for Adult Diffuse Glioma

The increasing expression of GPX7 related to the malignant clinical features leading to poor prognosis of glioma patients

Discovery of GJC1 as a prognostic biomarker in glioma cells: insights into its cell-cycle relationship and differential expression in non-neuronal cells

Comprehensive application of AI algorithms with TCR NGS data for glioma diagnosis

A combination of RNA-Seq and CHIP-Seq analysis for determining super enhancer- associated genes to evaluate prognosis and immunity of glioma